Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas van As

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
BJU International|November 15, 2011
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancerHashim U Ahmed, Oguz Akin, Jonathan A Coleman, et al.
The Lancet. Oncology|January 2, 2021
Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation studyAnastasia Chalkidou, Thomas Macmillan, Mariusz T Grzeda, et al.
International Journal of Radiation Oncology, Biology, Physics|February 19, 2020
Effect of <sup>18</sup>F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON TrialAndrew F Scarsbrook, David Bottomley, Eugene J Teoh, et al.
European Urology|September 12, 2024
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised TrialNicholas van As, Binnaz Yasar, Clare Griffin, et al.
Clinical and Translational Radiation Oncology|February 24, 2026
PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRTAngela Pathmanathan, Suneil Jain, John Staffurth, et al.
Clinical Genitourinary Cancer|June 3, 2017
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden HospitalDiletta Bianchini, David Lorente, Pasquale Rescigno, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
The New England Journal of Medicine|October 16, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNicholas van As, Clare Griffin, Alison Tree, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
BJU International|November 15, 2011
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancerHashim U Ahmed, Oguz Akin, Jonathan A Coleman, et al.
The Lancet. Oncology|January 2, 2021
Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation studyAnastasia Chalkidou, Thomas Macmillan, Mariusz T Grzeda, et al.
International Journal of Radiation Oncology, Biology, Physics|February 19, 2020
Effect of <sup>18</sup>F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON TrialAndrew F Scarsbrook, David Bottomley, Eugene J Teoh, et al.
European Urology|September 12, 2024
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised TrialNicholas van As, Binnaz Yasar, Clare Griffin, et al.
Clinical and Translational Radiation Oncology|February 24, 2026
PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRTAngela Pathmanathan, Suneil Jain, John Staffurth, et al.
Clinical Genitourinary Cancer|June 3, 2017
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden HospitalDiletta Bianchini, David Lorente, Pasquale Rescigno, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
The New England Journal of Medicine|October 16, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNicholas van As, Clare Griffin, Alison Tree, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
Pageof 6